Skip to main content

Table 1 Clinical features at presentation, in a study of 60 patients with blood culture-proven typhoid fever

From: Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi

Characteristic

Frequency, overall (n = 60)

NARST (n = 47)

NASST (n = 13)

MDR-ST (n = 22)

NonMDR-ST (n = 38)

Age, years *

15 ± 9

13 ± 9

23 ± 8

14 ± 9

16 ± 10

Gender (male/female)

40/20

32/15

8/5

15/7

25/13

Fever, days

8 (4.8–14)

10 (7–15)

4 (3–6)

9 (7–14.3)

7 (3.8–14)

Chills

39 (65)

30 (64)

9 (69)

15 (68)

24 (63)

Anorexia

58 (97)

46 (98)

12 (92)

22 (100)

36 (95)

Abdominal pain

23 (38)

18 (38)

5 (38)

10 (45)

13 (34)

Vomiting

33 (55)

27 (57)

6 (46)

14 (64)

19 (50)

Diarrhoea

27 (45)

22 (47)

5 (38)

11 (50)

16 (42)

Constipation

7 (12)

6 (13)

1 (8)

2 (9)

5 (13)

Intestinal bleeding

1 (2)

1 (2)

--

--

1 (3)

Headache

24 (40)

19 (40)

5 (38)

6 (27)

18 (47)

Altered sensorium

3 (5)

3 (6)

--

2 (9)

1 (3)

Cough

21 (35)

18 (38)

3 (23)

10 (45)

11 (29)

Relative bradycardia

6 (10)

4 (9)

2 (15)

1 (5)

5 (13)

Jaundice

3 (5)

3 (6)

--

--

3 (8)

Hepatomegaly §

29 (49)

27 (57)

2 (15)

11 (50)

18 (47)

Splenomegaly §

30 (51)

25 (53)

5 (38)

14 (64)

16 (42)

  1. NARST = nalidixic acid-resistant Salmonella typhi
  2. NASST = nalidixic acid-sensitive Salmonella typhi
  3. MDR-ST = multidrug-resistant Salmonella typhi
  4. -- no patients in this category
  5. All data presented as number (%) of patients, except when indicated
  6. * data presented as mean ± SD
  7. P-value < 0.05 for NARST vs. NASST; compared by independent t test or Mann-Whitney U test
  8. duration of fever at presentation; presented as median (IQR)
  9. § one patient with underlying chronic myeloid leukaemia was not included
  10. P-value < 0.05 for NARST vs. NASST; compared by Fisher's exact test